Aileron Therapeutics (ALRN) Sees Strong Trading Volume
Aileron Therapeutics Inc (NASDAQ:ALRN) saw unusually-strong trading volume on Tuesday . Approximately 1,375,894 shares were traded during mid-day trading, an increase of 348% from the previous session’s volume of 306,796 shares.The stock last traded at $2.12 and had previously closed at $1.40.
Several analysts have recently commented on ALRN shares. HC Wainwright started coverage on Aileron Therapeutics in a research note on Monday. They issued a “buy” rating and a $7.00 price objective for the company. ValuEngine downgraded Aileron Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Zacks Investment Research raised Aileron Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a report on Thursday, December 27th.
The firm has a market cap of $27.73 million, a PE ratio of -1.08 and a beta of 3.18. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.23 and a quick ratio of 4.23.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2019/03/14/aileron-therapeutics-alrn-sees-strong-trading-volume.html.
About Aileron Therapeutics (NASDAQ:ALRN)
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Further Reading: What is a put option?
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.